Milan, 15th June 2016
The Atrial Fibrillation is the most generally observed arrhythmia in the daily clinical practice and has a prevalence of almost 2%, increasing with increasing age. The presence of this arrhythmia represents an important risk factor for thromboembolic events, in particular for stroke that is 5 times more frequent, besides being mostly disabling, in individuals with Atrial Fibrillation compared to those without Atrial Fibrillation.
The clinical, economic and social load of stroke disease is higher in individuals with Atrial Fibrillation compared to those without Atrial Fibrillation, as strokes resulting from Atrial Fibrillation are mostly disabling.
A correct management of the patient suffering from this condition requires the use of different pharmacological therapies and the different health professionals (clinical, chemists, pharmacologists)